Antibiotic Treatment for Pneumonia in Patients with Bronchiectasis

Initial Risk Stratification

The European Respiratory Society recommends obtaining a sputum sample for culture and sensitivity before starting antibiotics, especially in patients requiring hospitalization 3
The American Thoracic Society suggests evaluating the severity of exacerbation, including oxygen saturation, spirometry, and arterial blood gas analysis if necessary, to guide treatment decisions 4
Previous colonization should be reviewed by examining previous sputum cultures to identify known pathogens 1, 2

The British Thoracic Society recommends amoxicillin-clavulanate 625 mg three times a day for 14 days as first-line treatment for patients without risk factors for Pseudomonas aeruginosa 1, 5
For patients with risk factors for Pseudomonas aeruginosa, such as bronchiectasis, the European Respiratory Society suggests ciprofloxacin 500-750 mg twice a day for 14 days as first-line oral treatment 1, 2, 5
The American College of Chest Physicians recommends ceftazidime 2g three times a day, piperacillin-tazobactam 4.5g three times a day, or meropenem 2g three times a day as monotherapy for intravenous treatment 1

The European Respiratory Society recommends a treatment duration of 14 days for patients with bronchiectasis, especially if infected with P. aeruginosa 1, 2
Empiric antibiotics should be adjusted or modified according to sputum culture results 3, 2
Patients may have an in vivo response despite in vitro resistance, particularly with P. aeruginosa 1, 5

If the patient does not respond to initial treatment, a reevaluation of non-infectious causes, such as inadequate medical treatment, embolism, or heart failure, should be performed 3
A careful microbiological reevaluation, including obtaining new cultures, should be conducted 3
Antibiotic change with good coverage against P. aeruginosa, S. pneumoniae, and non-fermenters, adjusting according to microbiological results, may be necessary 3

Using courses shorter than 14 days in the presence of P. aeruginosa should be avoided 1, 2
Initiating long-term macrolides without ruling out active infection by non-tuberculous mycobacteria with at least one negative respiratory culture should be avoided 2, 5
Caution should be exercised when using aminoglycosides in pregnancy, renal insufficiency, elderly patients, or those taking multiple concomitant medications 1
The need for intravenous therapy in particularly severe patients or those with resistant organisms should not be underestimated 1

Sputum should be sent for culture and sensitivity immediately before and at each clinical visit after antibiotics to determine treatment outcome 6
Periodic surveillance of colonization in patients with bronchiectasis may be considered 3